Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Goodwill & Intangibles (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Goodwill & Intangibles for 7 consecutive years, with $8.4 million as the latest value for Q2 2025.

  • On a quarterly basis, Goodwill & Intangibles rose 201.79% to $8.4 million in Q2 2025 year-over-year; TTM through Jun 2025 was $8.4 million, a 201.79% increase, with the full-year FY2024 number at $3.2 million, down 2.85% from a year prior.
  • Goodwill & Intangibles was $8.4 million for Q2 2025 at Vivos Therapeutics, up from $2.8 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $8.4 million in Q2 2025 to a low of $2.7 million in Q1 2021.
  • A 5-year average of $3.5 million and a median of $3.2 million in 2022 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: plummeted 40.98% in 2022, then soared 201.79% in 2025.
  • Vivos Therapeutics' Goodwill & Intangibles stood at $3.1 million in 2021, then grew by 0.13% to $3.1 million in 2022, then grew by 3.75% to $3.3 million in 2023, then decreased by 2.85% to $3.2 million in 2024, then soared by 166.56% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Goodwill & Intangibles are $8.4 million (Q2 2025), $2.8 million (Q1 2025), and $3.2 million (Q4 2024).